Healthcare and Life Science
Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases
Patents cover a polymorph (crystalline form) of PTD802, Pheno's lead clinical candidate, and a composition of matter covering PTD939, Pheno's second GPR17 antagonist PTD802, a small molecule therapeutic designed to promote remyelination in neurological and neurodegenerative&nb...
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) to enable high-resolution structural analysis of a G protein-coupled receptor (GPCR)Researchers achieved a 3.38 Å cryo-EM structure, with just 4 days from gene asse...
How long does it take to bring a hardware product to market?
The honest answer is that there is no single timeline, because no two hardware products are the same. How long it takes depends on how complex the product is, how much technical risk it carries, how much of it is genuinely new, and how in-depth the development project needs to be. A pro...
Calla Lily Clinical Care awarded Innovate UK grant to expand Callavid platform for vaginal microbiome health
£700k Growth Catalyst award supports adaptation of Callavid intravaginal drug delivery platform for live biotherapeutic products and probioticsProgramme addresses pressing need for new approaches to vaginal dysbiosis conditions and supports efforts to tackle antimicrobial resistanceLond...
Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001
Investigational inhaled ENaC blocker developed to treat people with cystic fibrosis not benefitting from CFTR modulatorsPositive opinion recognises potential of ETD001 in treating rare and severe diseaseDecision follows successful Phase 2 clinical trialBrighton, UK, 17 November 2026: En...
New protein maps could accelerate precision medicine
Researchers have developed new ways of identifying new druggable sites in two families of proteins that could help design new treatments, and drugs with fewer side effects, for a wide range of conditions, from heart disease to diabetes and cancer. ...
Run it like an experiment: what science and tech managers can learn from Lens Not Label
TL;DR: Pharmaceutical and technology organisations already have the best method there is for managing neurodivergent talent. They use it every day in the lab and in the codebase: form a view, test it, look at the evidence, adjust. Lens Not Label: A Conversational Guide for Working More ...
TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease
Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.Includes up to $32 million in upfront and research milestone payments, with total potential ...
Laverock Therapeutics appoints Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman
Appointment of experienced transatlantic leadership team, based in London and New York, to support lead programmes’ progression into the clinicInterim Chair Lisa Deschamps to transition to Non-Executive Director roleDavid Venables will step down as Chief Executive Officer on 31 December...
Guardtech partner with Intense Pulsed Light innovators Biopulz to offer game-changing new cleanroom decontamination solution
New partnership will give Guardtech clients access to Biopulz’s mobile Eloane tower and integrated E-z̈o IPL decontamination system as part of their cleanroom installation projects ...